| Covidien Buys Ev3 for $2.6 Billion Covidien said it is buying vascular device maker ev3 for $2.6 billion in cash as it continues to remake its business. online.wsj.com |
Positive Study Results for Migraine Drug Levadex Map Pharmaceuticals reported positive study data related to its investigational drug Levadex, an inhaled treatment for migraines. online.wsj.com |
Eli Lilly: A Strong Dividend Despite a Rough Year Eddy Elfenbein submits: This hasn't been a very good year for Eli Lilly (LLY). The shares are down again today on news that it will halt development of semagacestat, a potential Alzheimer's treatment. The preliminary tests just weren't working out. Lilly said that this will result in a Q3 charge of three to four cents per share. That's bad but not awful.Lilly confirmed its previous 2010 earnings per share guidance range of $4.44 to $4.59 on a reported basis, or $4.50 to $4.65 on a non-GAAP basis (consensus is for $4.61).Complete Story » seekingalpha.com |
Roche Bets Big on Parkinson's, Alzheimer's Programs The Burrill Report submits: By Michael FitzhughRoche (RHHBY.PK) will invest as much as $635 million (€500 million) in two of reMynd’s pre-clinical programs that are intended to slow the progression of Parkinson's and Alzheimer's diseases. Complete Story » seekingalpha.com |
U.K. Cost Body Declines to Back Cancer Drug The U.K. health-cost body has declined to back Novartis's kidney-cancer drug Afinitor as a second line treatment due to lingering cost and efficiency concerns. online.wsj.com |